Lung Cancer Screening Market (2026-2036)

The lung cancer screening market covers screening procedures and the associated reading and reporting, nodule detection and characterisation software, eligibility, registry and navigation software, risk prediction models, and biomarker tests used in screening, delivered through organised programmes and opportunistic clinical screening. The growth of this market is driven by the proportion of eligible people currently unscreened, by organised national programmes replacing opportunistic ordering, by software that identifies and qualifies eligible patients, and by blood-based tests entering risk stratification.

The American Lung Association 2026 Lung Health Barometer reports that only 24.5% of eligible individuals are currently being screened, with 24.8% among women and 24.0% among Black individuals, that only 25% of cases are diagnosed early on SEER 2022 data where the five-year survival rate climbs to 65%, and that among 4,000 people surveyed only 33% were aware of the screening available to those who are eligible. Three quarters of the eligible population is therefore unscreened and two thirds of the public is unaware the screening exists, which is the position after a grade B recommendation has been in force since 2021 and Medicare coverage since 2015.

The United States Preventive Services Task Force recommendation dated 9 March 2021 gives annual screening with low-dose computed tomography a grade B in adults aged 50 to 80 years with a smoking history of at least 20 pack-years who currently smoke or who quit within the past 15 years, following shared decision-making about the benefits, limitations and harms, and advises stopping once a person has not smoked for 15 years or when a health problem limits life expectancy or the ability to have lung surgery. The previous recommendation applied to ages 55 to 80 with a 30 pack-year history. National coverage determination 210.14, applying to claims with dates of service on or after 10 February 2022, requires a beneficiary to be 50 to 77 years old, to have no signs or symptoms of lung cancer, to have a smoking history of at least 20 pack-years, to be a current smoker or to have quit within the last 15 years, and to hold an order for the screening. A counselling and shared decision-making visit must take place before the first scan and be documented in the medical record, covering determination of eligibility, shared decision-making using one or more decision aids, counselling on annual screening adherence, the effect of comorbidities and the willingness to undergo diagnosis and treatment, and counselling on remaining smoke-free or on quitting with tobacco cessation interventions where appropriate. The reading radiologist must be board certified or board eligible with the American Board of Radiology or an equivalent organisation, and the imaging facility must use a standardised lung nodule identification, classification and reporting system. Eligibility turns on a smoking history measured in pack-years, which most medical records do not hold in structured form, so a health system cannot list its eligible population from its own data and the first task in this market is identification rather than imaging. The report therefore treats identification and recall capability as a segmentation dimension and as a competitive benchmark rather than as an operational detail of programme delivery.

Screening for lung cancer uses annual low-dose computed tomography in people whose smoking history places them at high risk, detecting nodules that are then classified and followed or investigated. Randomised evidence established a reduction in lung cancer mortality in screened populations, and the recommendation and coverage positions followed, so the question in this market has not been whether screening works for more than a decade.

The American Lung Association 2026 Lung Health Barometer reports that only 24.5% of eligible individuals are currently being screened, with 24.8% among women and 24.0% among Black individuals, that only 25% of cases are diagnosed early on SEER 2022 data where the five-year survival rate climbs to 65%, and that among 4,000 people surveyed only 33% were aware of the screening available to those who are eligible. A screening programme with established evidence, a grade B recommendation and national coverage that reaches a quarter of the eligible population is failing at delivery rather than at design, and the awareness figure indicates where the failure begins, since a person who does not know the screening exists will not raise it with a clinician and opportunistic screening depends on exactly that conversation.

The United States Preventive Services Task Force recommendation dated 9 March 2021 gives annual screening with low-dose computed tomography a grade B in adults aged 50 to 80 years with a smoking history of at least 20 pack-years who currently smoke or who quit within the past 15 years, following shared decision-making about the benefits, limitations and harms, and advises stopping once a person has not smoked for 15 years or when a health problem limits life expectancy or the ability to have lung surgery. The previous recommendation applied to ages 55 to 80 with a 30 pack-year history. The criteria are precise, which assists a payer and complicates everything else, because a clinician cannot determine eligibility without a quantified smoking history and a quit date, and both have to be elicited and recorded rather than retrieved.

A medical record may note that a patient smokes, smoked or has never smoked, but the quantity and duration needed to compute 20 pack-years and the date of quitting are usually absent or recorded in free text, so a health system cannot generate a list of its eligible patients from its own data in the way it can for colorectal or breast screening where age and sex suffice. Identification is consequently a data problem before it is a clinical one.

National coverage determination 210.14, applying to claims with dates of service on or after 10 February 2022, requires a beneficiary to be 50 to 77 years old, to have no signs or symptoms of lung cancer, to have a smoking history of at least 20 pack-years, to be a current smoker or to have quit within the last 15 years, and to hold an order for the screening. A counselling and shared decision-making visit must take place before the first scan and be documented in the medical record, covering determination of eligibility, shared decision-making using one or more decision aids, counselling on annual screening adherence, the effect of comorbidities and the willingness to undergo diagnosis and treatment, and counselling on remaining smoke-free or on quitting with tobacco cessation interventions where appropriate. The reading radiologist must be board certified or board eligible with the American Board of Radiology or an equivalent organisation, and the imaging facility must use a standardised lung nodule identification, classification and reporting system. A documented counselling and shared decision-making visit before the first scan places a clinician appointment ahead of every imaging appointment, which is a second gate in a pathway whose first gate is identification, and attrition occurs at both. The facility and radiologist requirements also restrict where screening can be performed and who can report it.

The age ranges of the recommendation and of Medicare coverage do not match. The task force recommends screening to age 80 while Medicare covers to 77, so a person aged 78 to 80 holds a grade B recommendation without Medicare coverage for the scan, which is a narrow but real discontinuity in the pathway and one a clinician has to explain.

Organised programmes that invite an eligible population directly achieve participation far above opportunistic ordering, which is why national and regional programmes are being established rather than left to clinical discretion. Such a programme has to solve identification at population level, generally by combining primary care records, risk models and direct questionnaires, and the infrastructure it builds for that purpose is the part of the pathway that opportunistic screening lacks entirely.

A low-dose scan finds nodules in a substantial proportion of those screened, most of which are benign, and the value of the programme depends on classifying them consistently so that the few requiring investigation are pursued and the many that do not are followed without further procedures. The Medicare requirement for a standardised nodule identification, classification and reporting system reflects that, and software supporting it is purchased for exactly that reason.

Risk models that estimate individual probability from age, smoking history, family history, comorbidity and other factors select a higher-risk population than fixed criteria do at the same volume of scanning, and several organised programmes use them in place of or alongside pack-year thresholds. That approach raises the cancers detected per scan performed, which is the measure a programme is funded against, and it also admits people whose smoking history falls below a fixed threshold but whose overall risk is high.

Blood-based testing is entering this market as risk stratification rather than as a replacement for imaging, because a blood test identifies people who warrant a scan rather than removing the need for one, and a nodule still has to be located and characterised. That position is narrower commercially than a screening test but it addresses the identification problem directly, which is where this market is constrained. A blood test reaching the standard required to replace imaging would change the market entirely, but none is approved and the evidence required would take the better part of a decade to generate.